Modular CRISPR system
Through the modular CRISPR-Cas system, the CRISPR-Cas protein is fused with the binding peptide, solving the problem of production difficulties caused by large size of the fusion protein, and achieving faster and simpler genome editing efficiency.
Patent Information
- Application Number
- CN202380075233.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-10-31
- Filing Date
- 2023-10-31
- Publication Date
- 2025-06-06
AI Technical Summary
When existing CRISPR-Cas systems apply more advanced base editing and initiation editing techniques in RNP delivery, they face problems such as the large size of the fusion protein, which leads to difficult, time-consuming and expensive production in bacterial systems.
The modular CRISPR-Cas system is adopted, where the CRISPR-Cas protein is fused with the binding peptide, which can be expressed and purified independently, making it easy to assemble into ribonucleoprotein (RNP) for genome editing.
The protein production and purification process is simplified, and the flexibility and efficiency of the CRISPR-Cas system is improved, allowing for faster and simpler genomic modification or homologous directed repair.
Smart Images

Figure CN120112647A_ABST
Abstract
Description
Technical Field
[0001] The techniques presented herein generally relate to the field of genome editing using CRISPR-Cas systems.
[0002] background
[0003] DNA is a molecule that stores genetic information and serves as a blueprint for any living organism on Earth. Manipulating genetic information can change an organism. Humans have done this indirectly to breed crop species with beneficial characteristics, such as higher yields or better robustness. Plants that exhibit preferred characteristics are selected for breeding. In this way, plants with superior traits are created.
[0004] Climate change and population growth already pose serious challenges to food security and agribusiness on a global scale. A key component to achieving more sustainable agriculture that can adapt to changing environmental conditions may be the emergence of genome editing, a form of genetic engineering that allows precise edits without introducing foreign DNA into the target organism. At the heart of genome editing are the gene scissors CRISPR-Cas, which can be programmed to make edits at specific locations in the genome.
[0005] CRISPR-Cas systems introduce DSBs at specific locations, but repair by non-homologous end joining (NHEJ) is rather random, and screening for desired mutations can be laborious. Recent advances have enabled more precise editing and alterations. Two different approaches are primarily used: base editors (BE) and primary editors (PE). Both systems involve fusing a functional protein to a variant of Cas9.
[0006] The first generation of BE used a catalytically inactive Cas9 (dCas9), a variant in which both cleavage domains were inactivated by mutation, but RNA-programmable binding to DNA was retained. dCas9 was then fused to a cytidine deaminase. Deamination of cytidine (C) produces uracil (U), which is recognized by the DNA repair machinery and replaced by thymine (T). Therefore, this method converts C:G base pairs to A:T without introducing DSBs, and is therefore called cytosine base editors (CBEs).
[0007] The third generation of CBEs achieved higher editing efficiency with a Cas9 nickase (nCas9) in which only the RuvC domain was inactivated. The development of adenine base editors (ABEs) enabled conversion of all four nucleotides by fusing nCas9 to adenosine deaminase (obtained through extensive protein engineering).
[0008] PE provides higher versatility. Here, nCas9 is fused with murine leukemia virus (MMLV)-reverse transcriptase (RT). The programmable RNA has a 3' extension with a primer binding site (PBS) and is called a guide editing guide RNA (pegRNA). In this system, nCas9 dislocates the target strand by binding to the 5' end of the pegRNA. Afterwards, the non-target strand is cleaved by the RuvC nuclease domain of nCas9, introducing a nick in the DNA. The PBS can now hybridize with the free 3' end of the target DNA, acting as a primer for RT, which reverse transcribes RNA to incorporate the desired sequence into the target DNA. Therefore, any sequence after the PBS of the pegRNA can be inserted into the DNA, which creates a powerful "search and replace" tool. The engineering of MMLV-RT, cutting the non-editing strand and including the PAM sequence in the editing, produces a PE system with significantly improved efficiency. In theory, any deletion up to 44bp and insertion up to 80bp can be achieved. So far, more than 50 types of BE and PE have been developed, each of which has very specific advancements and different application ranges.
[0009] Depending on the application, the CRISPR-Cas system can be delivered to cells in different forms: as DNA, as mRNA, and as a protein complex. In addition, DNA can be transfected in a transient or stable manner. The former refers to the introduction of the CRISPR-Cas system as DNA via a plasmid vector that is not integrated into the genomic DNA of the cell. Plasmid DNA can be delivered, for example, by means of a gene gun or PEG transformation. For transient transformation, the plasmid is usually lost after cell division. In contrast, stable integration of transgenes leads to sustained expression, which is maintained for several generations. Some of the most common techniques for stably integrating transgenes into plant genomes are biolistics or Agrobacterium-mediated transformation. Stably transformed plants can be made transgenic-free by self-pollination or hybridization, in which only the desired mutations are retained in the genome.
[0010] However, in both cases, recombinant DNA is introduced into the cell, which can pose a risk of unpredictable side effects. Delivery of mRNA encoding CRISPR-Cas enables faster expression and bypasses the risk of insertional mutagenesis. However, delivery in the form of mRNA is always transient, as RNA is highly unstable and rapidly degrades.
[0011] Finally, delivering CRISPR-Cas in the form of protein allows transient CRISPR activity and avoids the risk of introducing recombinant DNA into cells. Specifically, before transfection, guide RNA (gRNA) is loaded to CRISPR-Cas protein, and then delivered to cells as ribonucleoprotein (RNP). The means of delivery in plants include, for example, biolistics that allow cell wall penetration, microinjection during sexual reproduction, and protoplast transfection. The main steps of the latter workflow include: separating protoplasts from plant tissues, RNP assembly and delivery to protoplasts, and protoplasts are then regenerated into whole plants. This transgenic-free method is advantageous because it prevents the non-predetermined effects from recombinant DNA.
[0012] Although RNP delivery has been successfully developed in several plant species using standard CRISPR-Cas technology, it remains a challenge to apply more advanced BE and PE methods in RNP delivery. This is mainly due to the large size of BE and PE fusion proteins, which makes it difficult, time-consuming and expensive to produce large amounts of high-quality proteins in bacterial systems. Successful attempts to produce fusion proteins in mammalian cells have been made, however, eukaryotic protein expression is more resource-intensive. For example, Rees et al., 2017 successfully produced BE fusion proteins in Escherichia coli (E. coli) only after extensive optimization steps (including testing a variety of different expression strains and constructs to achieve sufficient yields). Therefore, laborious optimization steps will limit the field of application.
[0013] Therefore, there is a need for further development and implementation of base editing and prime editing with CRISPR-Cas for RNP delivery.
[0014] WO2021165508 discloses an expression cassette comprising a type II or type V CRISPR-Cas effector protein domain fused to a peptide tag and a reverse transcriptase domain fused to an affinity peptide.
[0015] US20200017869 discloses a recombinant vector comprising: a first nucleic acid sequence comprising a plant promoter and encoding a recombinant polypeptide, wherein the recombinant polypeptide comprises a nuclease-deficient CAS9 polypeptide (dCAS9) or a fragment thereof and a multimeric epitope; a second nucleic acid sequence comprising a plant promoter and encoding a recombinant polypeptide, wherein the recombinant polypeptide comprises a transcription activator and an affinity polypeptide that specifically binds to the epitope; and a third nucleic acid sequence comprising a promoter and encoding crRNA and tracrRNA or a fusion thereof.
[0016] The purpose of the technique proposed in this paper
[0017] The first aim of the technology presented herein is to provide a modular CRISPR-Cas system that allows for faster and simpler genome modification using base editing (BE) and primer editing (PE) or for homology-directed repair (HDR), in particular using ribonucleoprotein delivery.
[0018] A second purpose of the technology presented herein is to provide methods for assembling CRISPR-Cas complexes.
[0019] A third purpose of the technology presented herein is to provide a CRISPR-Cas complex.
[0020] A fourth objective of the technology presented herein is to provide the use of a modular CRISPR-Cas system or a CRISPR-Cas complex for modifying the genome of an organism.
[0021] Overview
[0022] At least one of the above-mentioned objects, or at least one of the additional objects that will become apparent from the following description, is obtained according to a first aspect of the technology presented herein by a modular CRISPR-Cas system comprising:
[0023] - a CRISPR-Cas protein fused to a first binding peptide,
[0024] - a functional protein fused to a second binding peptide,
[0025] Wherein the first binding peptide and the second binding peptide are configured to bind to each other and define a binding peptide pair.
[0026] Therefore, the technology proposed herein is based on the recognition of the inventors that the production of fusion proteins of CRISPR-Cas and functional proteins is a limiting factor for the use of RNP delivery CRISPR-Cas systems. Therefore, it should be understood that the modular CRISPR-Cas system is suitable for or arranged for use in ribonucleoprotein (RNP) delivery. In other words, the modular CRISPR-Cas system is an in vitro modular CRISPR-Cas system. Not only must the correct DNA sequences of CRISPR-Cas proteins and functional proteins be obtained and fused together, but the expression of fused DNA sequences also involves difficulties. If the desired peptide sequence corresponding to the fusion protein is obtained, it is difficult to separate and purify these relatively large fusion proteins from host cells. It is understandable that a high level of purity is required, which leads to a low yield of the fusion protein. Finally, even if a successful transfection has been obtained with a fusion protein, if a different fusion protein is to be used, the production process (fusion DNA, expression of fused DNA, purification of fusion protein) must be restarted. Therefore, when a first fusion protein comprising a first CRISPR-Cas and a first functional protein is available, great efforts are required if it is desired, for example, to use the first CRISPR-Cas together with a second, different functional protein.
[0027] The CRISPR-Cas system according to the first aspect of the technology proposed herein solves all of these limitations. By using binding peptides, CRISPR-Cas proteins can be made, that is, expressed and purified separately from functional proteins, which greatly simplifies the production process, especially the purification process, because these proteins are smaller in size compared to fusion proteins. In addition, by providing CRISPR-Cas proteins separated from functional proteins, it is easy to change or modify the function of CRISPR-Cas proteins by pairing CRISPR-Cas proteins with different functional proteins. Pairing can be accomplished by simply mixing CRISPR-Cas proteins with functional proteins. Therefore, this allows the capabilities of the CRISPR-Cas system to be further expanded because it allows the addition of additional functions, including functions that have not yet been used with CRISPR-Cas systems based on fusion proteins. This provides novel and enhanced genome editing possibilities.
[0028] Therefore, the technology proposed in this article provides a modular CRISPR-Cas system, in which different CRISPR-Cas proteins and functional proteins can be combined to form ribonucleoproteins, and then the ribonucleoproteins are provided to the cells to be modified. The combination of CRISPR-Cas proteins and functional proteins is performed outside the cell, for example, in vitro, and is therefore easy to perform. The modularity of the system is obvious, because after various CRISPR-Cas proteins and functional proteins are manufactured, they can be combined as desired to form different ribonucleoproteins without the need to edit or change the vectors and sequences used to express CRISPR-Cas proteins and functional proteins. In addition, the gRNA guiding the CRISPR-Cas system is also combined with the CRISPR-Cas protein in vitro, thereby making it simple to select and / or change the target gene to be modified.
[0029] In addition, by combining CRISPR-Cas proteins and functional proteins and gRNA in vitro, the assembly order of ribonucleoproteins can be determined. If the functional protein itself has RNA interactions or affinity, this can be important to prevent premature compounding between gRNA and functional proteins. Assembling CRISPR-Cas-complexes with gRNA in vitro rather than in vivo can further prevent gRNA from interacting with other cellular components (such as proteins, RNA and DNA) present in cells (i.e. in vivo). Assembling CRISPR-Cas-complexes in vitro with gRNA also allows the molar ratio of components to be controlled.
[0030] In summary, the technology proposed in this article therefore provides multiple advantages over, for example, WO2021165508 and US20200017869.
[0031] The modular CRISPR-Cas system is suitable for ribonucleoprotein (RNP) delivery or is arranged for use in ribonucleoprotein (RNP) delivery. Therefore, the CRISPR-Cas protein and the functional protein are in a form suitable for forming a ribonucleoprotein (RNP), which is in a form suitable for delivery to a cell.
[0032] In the context of the technology presented herein, the equivalent terms "for ribonucleoprotein (RNP) delivery" and "suitable for ribonucleoprotein (RNP) delivery" and "arranged for use in ribonucleoprotein (RNP) delivery" encompass that ribonucleoprotein (RNP) delivery can be used with a modular CRISPR-Cas system. In other words, a modular CRISPR-Cas system can be used with ribonucleoprotein (RNP) delivery.
[0033] In the context of the technology presented in this article, the terms CRISPR-Cas system and CRISPR system are used interchangeably.
[0034] In the context of the technology presented herein, the term modularity when applied to the CRISPR-Cas system means that the CRISPR-Cas system encompasses different possible modules, wherein, for example, the CRISPR-Cas protein and its first binding peptide define the first module, and the functional protein and its second binding peptide define the second module. Typically, the system may include additional modules, such as a third module defined by additional functional proteins, the third module also having a second binding peptide configured to bind to the first binding peptide. Therefore, the modular CRISPR-Cas system allows the assembly of a CRISPR-Cas complex by selecting a desired CRISPR-Cas protein and its first binding peptide and assembling it with a desired functional protein and its second binding peptide, thereby assembling any desired CRISPR-Cas complex customized for, for example, base editing, priming editing, or other types of editing as desired.
[0035] Specifically, the selection and assembly of CRISPR-Cas proteins and functional proteins is performed on the proteins, rather than on the genes encoding the proteins. This allows for easy assembly, i.e., by contact such as by mixing, and does not require modification or genes encoding CRISPR-Cas proteins and functional proteins.
[0036] The CRISPR-Cas system may, for example, comprise first more than one first modules corresponding to different CRISPR-Cas proteins with different activities and second more than one second modules corresponding to functional proteins with different functions, to allow users of the system to obtain any desired combination of CRISPR-Cas proteins and functional proteins.
[0037] The CRISPR-Cas system can exist in an assembled form as a CRISPR-Cas complex, i.e., the first binding peptide is bound to the second binding peptide, or in a non-assembled form, i.e., wherein the first binding peptide and the second binding peptide are not bound to each other, and the CRISPR-Cas protein and the functional protein are therefore not associated as a CRISPR-Cas complex.
[0038] The CRISPR-Cas protein can be, for example, a Cas9 (dCas9) or a Cas9 nickase (nCas9) without catalytic activity. Typically, the CRISPR-Cas protein can be any CRISPR-Cas-related protein or portion thereof, which is an RNA-guided DNA endonuclease, such as CRISPR-Cas9, CRISPR-Cas12a, or a variant thereof. The CRISPR-Cas protein can have two, one, or none of the functional nuclease domains.
[0039] The CRISPR-Cas protein is preferably fused to the first binding peptide by expressing them sequentially with the first binding peptide.
[0040] The first binding peptide and the second binding peptide generally each have a length of 10-170 amino acids. The first binding peptide and the second binding peptide are configured to bind to each other. The binding can be the result of the attraction between the side chains of the amino acids constituting the corresponding binding peptides.
[0041] In the context of the technology presented herein, the term peptide encompasses peptides, polypeptides and proteins.
[0042] Functional proteins are proteins that can change or affect the results of applying CRISPR-Cas proteins to DNA. Therefore, functional proteins can be configured to affect the function of CRISPR-Cas proteins. Alternatively, functional proteins are configured to affect how an organism whose genome or DNA is affected by CRISPR-Cas proteins handles effects caused by the action of CRISPR-Cas proteins, such as breaks. Therefore, functional proteins can, for example, affect how to repair breaks in DNA chains. Therefore, improving directed repair such as homology-directed repair or homologous recombination is an additional feature that can be provided by functional proteins.
[0043] The first binding peptide and the second binding peptide together define a binding peptide pair. Different binding peptide pairs are known in other technical fields. By designing the sequences of the first binding peptide and the second binding peptide so as to bind to each other through the side chains, the binding peptide pair can be further synthetically constructed. In particular, the first binding peptide and the second binding peptide can be constructed so as to present a secondary structure suitable for binding, i.e. as an alpha-helix or a beta fold.
[0044] The binding peptide pair preferably comprises the cohesin / Dockerin system.
[0045] As shown in the Examples, the cohesin / Dockerin system, i.e., wherein one of the first binding peptide and the second binding peptide comprises or consists of cohesin and the other comprises or consists of Dockerin, works well in the CRISPR-Cas system.
[0046] Typically, the binding peptide pair can comprise a first binding peptide having at least 90% sequence identity, such as at least 95% or at least 99% sequence identity, to one of cohesin and Dockerin, and a second binding peptide having at least 90% sequence identity, such as at least 95% or at least 99% sequence identity, to the other of cohesin and Dockerin.
[0047] In other words, the binding peptide pair can comprise a first binding peptide having at least 90% sequence identity, such as at least 95% or at least 99% or 100% sequence identity, to one of SEQ ID NO: 19 and SEQ ID NO: 21 (see below) and a second binding peptide having at least 90% sequence identity, such as at least 95% or at least 99% or 100% sequence identity to the other of SEQ ID NO: 19 and SEQ ID NO: 21.
[0048] The amino acid sequence of the cohesin domain Cip7 is given by SEQ ID NO: 19:
[0049]
[0050] In the following additional examples, the DNA sequence used to express the cohesin domain Cip7 is given by SEQ ID NO: 20, wherein nucleotides 31-459 (underlined) encode cohesin:
[0051]
[0052] The amino acid sequence of the Dockerin domain Doc1 is given by SEQ ID NO:21:
[0053]
[0054] In the following additional examples, the DNA sequence for expressing the Dockerin domain Doc1 is given by SEQ ID NO: 22, wherein nucleotides 167-373 (underlined) encode Dockerin. In this sequence, the sequence of Dockerin is preceded by the c-terminus of Cas9 (first 155 nucleotides) and followed by the sequence of NLS (nucleotides 373-394):
[0055]
[0056] The peptide binding pairs may comprise other peptide systems in which a first peptide is configured to bind to a second peptide. Possible systems also include the FK506 binding protein 12 (FKBP)-FKBP rapamycin binding (FRB) domain system.
[0057] Preferably, the functional protein is selected from the group consisting of:
[0058] a) a deaminase, preferably a modified deaminase,
[0059] b) reverse transcriptase,
[0060] c) methylase, and
[0061] d) Homologous recombination and homology-directed repair enhancing proteins.
[0062] In other words, the functional protein is preferably a deaminase, a reverse transcriptase, a methylase or a homologous recombination protein or a homology-directed repair enhancing protein.
[0063] Each of these types of functional proteins influences or alters the outcome of applying the CRISPR-Cas protein to DNA.
[0064] Deaminases are used, for example, in base editing (BE). Examples include cytidine deaminase, which deaminates cytidine (C) to produce uracil (U). This functional protein can be used with a catalytically inactive Cas9 (dCas9). Another example is adenosine deaminase, which can be used with a nickase (nCas9).
[0065] In primed editing (PE), the functional protein can be a reverse transcriptase, which is used together with a nickase (nCas9).
[0066] Methylases add methyl groups to adenine or cytosine bases within the recognition sequence, thereby protecting these bases.
[0067] Homologous recombination and homology-directed repair enhancer proteins function by inhibiting the NHEJ repair machinery, improving the accessibility of DNA to homologous recombination, or directing the repair template to the CRISPR-Cas interaction site.
[0068] It is further expected in the context of the technology proposed herein that the functional protein may be optionally a RAD protein, such as a RAD51 protein. RAD proteins, such as RAD51 proteins, can bind to DNA at the site of the break and wrap the DNA in a protein sheath. Therefore, by using RAD proteins as functional proteins, the effect of CRISPR-Cas proteins can be further modified. A bacterial protein similar to RAD is the RecA protein.
[0069] The modular CRISPR-Cas system according to the first aspect of the technology presented herein may further comprise:
[0070] -Guide RNA sequence complex bound to CRISPR-Cas protein.
[0071] The guide RNA sequence (gRNA) directs the CRISPR-Cas protein to the target DNA.
[0072] The guide RNA can be provided as a combination with the CRISPR-Cas protein, or can be optionally provided separately from the CRISPR-Cas protein, so that the guide RNA can be assembled with the CRISPR-Cas protein by contacting the guide RNA with the CRISPR-Cas protein. The guide RNA can also be further functionalized by additionally providing a template, pegRNA, for genome editing by priming editing.
[0073] Preferably, the modular CRISPR-Cas system according to the first aspect of the technology presented herein comprises:
[0074] - a first container comprising a CRISPR-Cas protein fused to a first binding peptide,
[0075] - a second container containing a functional protein fused to a second binding peptide,
[0076] This is advantageous because it allows users of the modular CRISPR-Cas system to combine the CRISPR-Cas protein with a desired functional protein. Thus, embodiments of the modular CRISPR-Cas system such as a kit can be provided that allow users to perform both base editing and priming editing by selecting the corresponding CRISPR-Cas protein and the functional protein from the same kit. Thus, the system can be implemented as a kit comprising at least one CRISPR-Cas protein and its corresponding first binding peptide, more preferably at least two, such as one dCas9 and one nCas9, and at least one functional protein and its corresponding second binding peptide, preferably at least two, such as one deaminase and one reverse transcriptase.
[0077] The first container and the second container can be any type of container capable of containing the CRISPR-Cas protein or the functional protein, but are preferably test tubes, such as plastic test tubes, for example Eppendorf tubes or glass test tubes. Thus, the CRISPR-Cas protein and the functional protein can be provided in a buffer or solution. It is further contemplated that the CRISPR-Cas protein and the functional protein can be provided in a solid form, such as a dried form or a crystalline form.
[0078] Preferably, the modular CRISPR-Cas system according to the first aspect of the technology presented herein comprises:
[0079] - an additional functional protein fused to a third binding peptide, wherein the additional functional protein is different from the functional protein, and wherein the third binding peptide is configured to bind to the first binding peptide, and wherein the third binding peptide preferably has the same amino acid sequence as the second binding peptide, and wherein the modular CRISPR-Cas system preferably further comprises:
[0080] - a third container comprising an additional functional protein fused to a third binding peptide.
[0081] This is advantageous because it provides a basic option for selecting which functional protein to use with the CRISPR-Cas protein.The third container may be of the same type as the second container described above.
[0082] The third binding peptide is configured to bind to the first binding peptide. The third binding peptide may have an amino acid sequence that has at least 90%, such as at least 95%, and more preferably at least 99% sequence identity with the amino acid sequence of the second binding peptide. Even more preferably, the third binding peptide has the same amino acid sequence as the second binding peptide.
[0083] It is also possible that the system comprises two or more groups of binding peptide pairs. In this case, each group of the binding peptide pairs comprises a first binding peptide fused to the CRISPR-Cas protein as described above and a second binding peptide fused to the functional protein. This allows a variety of functional proteins to be used together with the CRISPR-Cas protein. In this case, it is preferred that the sequences of the first binding peptide and the second binding peptide of each group of binding peptide pairs are configured so that the first binding peptide of the first group of binding peptide pairs only binds to the second binding peptide of the same group of binding peptide pairs, and therefore does not bind to the second binding peptide of another group of binding peptide pairs.
[0084] Preferably, the additional functional protein fused to the third binding peptide is provided in its own buffer or in solid form, such as dried or crystalline form.
[0085] A second aspect of the technology presented herein relates to a method of assembling a CRISPR-Cas complex comprising the following steps:
[0086] i. providing a system according to the first aspect of the technology presented herein, and
[0087] ii. bringing the CRISPR Cas protein fused to the first binding peptide and the functional protein fused to the second binding peptide into contact with each other,
[0088] The method preferably further comprises the following steps:
[0089] iii. Contacting the CRISPR Cas protein with the guide RNA sequence.
[0090] Step iii may be performed before step ii.
[0091] Therefore, it should be understood that the CRISPR-Cas complex is suitable for or arranged for use in ribonucleoprotein (RNP) delivery. In other words, the CRISPR-Cas complex is an in vitro modular CRISPR-Cas system.
[0092] The contacting of the CRISPR-Cas protein with its first binding peptide and the functional protein with its second binding peptide is preferably carried out by mixing. Therefore, the CRISPR-Cas protein with its first binding peptide and the functional protein with its second binding peptide are preferably provided in separate buffer solutions so that the buffer solutions can be mixed to assemble the CRISPR-Cas complex.
[0093] Alternatively, the CRISPR-Cas protein and its first binding peptide and the functional protein and its second binding peptide may be provided as solids in a crystalline form and mixed together in a buffer to assemble the CRISPR-Cas complex.
[0094] Similarly, the guide RNA sequence can be provided in a buffer for mixing with the CRISPR-Cas protein.As described above, the guide RNA can be modified, for example as a pegRNA.
[0095] Step ii of contacting the CRISPR-Cas protein with its first binding peptide and contacting the functional protein with its second binding peptide is performed in vitro. In other words, the contact is performed outside the cell to which the CRISPR-Cas-complex will be delivered as a ribonucleoprotein.
[0096] Step iii of contacting the CRISPR Cas protein with the guide RNA sequence can be performed before or after step ii of contacting the CRISPR Cas protein fused to the first binding peptide and the functional protein fused to the second binding peptide with each other. Step iii is performed in vitro. In other words, the contact is performed outside the cell to which the CRISPR-Cas-complex will be delivered as a ribonucleoprotein.
[0097] When the functional protein itself has RNA interaction or affinity, it may be advantageous to perform step iii before step ii to prevent complexing between the gRNA and the functional protein. Assembling the CRISPR-Cas-complex with the gRNA in vitro rather than in vivo can further prevent the gRNA from interacting with other cellular components (such as proteins, RNA, and DNA) present in the cell (i.e., in vivo).
[0098] A third aspect of the technology presented herein relates to a CRISPR-Cas complex obtained by the method according to the second aspect of the technology presented herein, i.e. a CRISPR-Cas complex for ribonucleoprotein (RNP) delivery, the CRISPR-Cas complex comprising:
[0099] - a CRISPR-Cas protein fused to a first binding peptide,
[0100] - a functional protein fused to a second binding peptide,
[0101] wherein the first binding peptide and the second binding peptide bind to each other,
[0102] And wherein the CRISPR-Cas complex preferably further comprises:
[0103] -Guide RNA sequence complex bound to CRISPR-Cas protein.
[0104] Therefore, it should be understood that the CRISPR-Cas complex is suitable for or arranged for use in ribonucleoprotein (RNP) delivery. In other words, the CRISPR-Cas complex is an in vitro modular CRISPR-Cas system.
[0105] When the first binding peptide and the second binding peptide are bound to each other, the CRISPR-Cas complex corresponds to the system according to the first aspect of the technology presented herein. The CRISPR-Cas complex can be used to modify DNA in vivo or in vitro, and the DNA can be free (isolated DNA) or in a cell or organism (genomic DNA).
[0106] A fourth aspect of the technology presented herein relates to use of a modular CRISPR-Cas system according to the first aspect of the technology presented herein or a CRISPR-Cas complex according to the third aspect of the technology presented herein for modifying the genome of an organism, wherein the organism is preferably a plant selected from the group consisting of monocotyledons and dicotyledons, or the organism is a plant selected from the group consisting of corn, rice, sorghum, rye, barley, wheat, millet, oats, sugarcane, lawn grass or switchgrass, soybean, rapeseed, alfalfa, sunflower, cotton, tobacco, peanut, potato, sugar beet, grape, Arabidopsis and safflower, and wherein preferably the organism is a plant from the Solanaceae family, preferably from the genus Solanum, more preferably from the species Solanum tuberosum.
[0107] The use may include using the modular CRISPR-Cas system according to the first aspect of the technology proposed herein or the CRISPR-Cas complex according to the third aspect of the technology proposed herein to modify the genome of a cell of an organism (such as a plant cell). After obtaining a plant whose genome is modified, the plant cell may be cultured as known in the art to obtain a plant. The finished plant may then be propagated and / or cultivated in turn to obtain other plants for planting and farming.
[0108] The organism is preferably not a human embryo. The use according to the fourth aspect of the technology presented herein preferably does not include modifying the germline genetic identity of a human. In addition, the use according to the fourth aspect of the technology presented herein preferably does not include surgery or therapeutic methods for treating the human or animal body.
[0109] Therefore, a fifth aspect of the technology presented herein relates to a plant obtained by the use according to the fourth aspect of the technology presented herein.
[0110] Correspondingly, the sixth aspect of the technology presented herein relates to a plant comprising or consisting of one or more plant cells, wherein the genome of the one or more plant cells has been modified by the use according to the fourth aspect of the technology presented herein.
[0111] A seventh aspect of the technology presented herein relates to progeny of a plant according to the fifth or sixth aspect of the technology presented herein.
[0112] An eighth aspect of the technology presented herein relates to seeds or spores obtained from a plant according to the fifth or sixth aspect of the technology presented herein.
[0113] A ninth aspect of the technology presented herein relates to an object capable of vegetative propagation of a plant according to the fifth or sixth aspect of the technology presented herein, such as a cutting or a scion or a tuber or a bulb or a callus.
[0114] BRIEF DESCRIPTION OF THE DRAWINGS AND DETAILED DESCRIPTION
[0115] A more complete understanding of the above and other features and advantages of the technology presented herein will be apparent from the following detailed description taken in conjunction with the accompanying drawings, in which:
[0116] Figure 1A The Cas9 protein is shown assembled with green fluorescent protein (GFP) by a first binding peptide and a second binding peptide, which are shown as Dockerin peptide (D) and cohesin peptide (C).
[0117] Figure 1BA Cas9 complex is shown, comprising a Cas9 protein assembled with a reverse transcriptase (RT) via a first binding peptide and a second binding peptide, shown as a Dockerin peptide (D) and a cohesin peptide (C).
[0118] Figure 2A A schematic overview of the constructs of the three clones is shown. Upper figure: Cas9-Doc1 (Cas 9 with 2.1 kbp corresponding to 158 kDa, Doc 1 with 0.2 kbp corresponding to 7 kDa), middle figure: Cip7-GFP (Cip7 with 0.4 kbp corresponding to 15 kDa, GFP with 0.7 kbp corresponding to 27 kDa (GFPuv)), lower figure: Cip7-RT (Cip7 with 0.4 kbp corresponding to 15 kDa, RT with 2.1 kbp corresponding to 77 kDa (MMLV-RT)). In each construct, the T7 promoter controls expression, allowing inducible proteins to be expressed in the Rosetta (DE3) E. coli strain. Kanamycin resistance (KanR) is used as a selection marker in all constructs. The nuclear localization sequence (NLS) is followed by the SpCas9 gene, which is fused to the first adapter component Doc1. The second adaptor component, Cip7, is fused to either GFP or Moloney murine leukemia virus reverse transcriptase (MMLV-RT).
[0119] Figure 2B Restriction analysis verifying the structure of the plasmid and successful transformation is shown. Plasmid DNA was purified from transformed and untransformed Rosetta (DE3) cells, digested with HindIII and BglII, and compared with the restriction pattern of the respective plasmid used for transformation. The band that may represent pRARE is indicated by an arrow.
[0120] Figure 3 Cas9 in vitro cleavage assay is shown to confirm nuclease activity. a, Patatin 1 PCR fragment was incubated with commercial TrueCut Cas9 or purified Cas9-Doc1 and gRNA. The reaction was run on an agarose gel. b, Sequence of gRNA and position in the target DNA fragment.
[0121] Figure 4 A PAGE showing the interaction of Cip7-GFP and Cas9-Doc1 is shown. Cip7-GFP and Cas9-Doc1 were loaded onto a non-denaturing gel with increasing amounts of the latter. TrueCut Cas9 was used as a negative control. The values depicted are in pmol. After electrophoresis, the gel was imaged for GFP signal.
[0122] Figure 5Shown is an electrophoretic mobility shift assay (EMSA) of Cas9 with GFP imaging. By removing the final heating step, the Cas9 in vitro cleavage assay ( Figure 3 ) was adapted to EMSA, which allows Cas9 to remain associated with the target DNA resulting in a mobility shift. After electrophoresis, the gel was imaged for GFP signal and then DNA was stained using the GelRed post-staining protocol. GFP bands with clear interactions between Cip7-GFP+Cas9-Doc1 are indicated with arrows.
[0123] Figure 6 Cas9 electrophoretic mobility shift assay (EMSA) with Cip7-GFP and Cip7-RT is shown. The experimental setup is similar to Figure 5 , but using less DNA and protein, and extending the run time to achieve better separation. The amount of Cas9-Doc1 was kept constant while increasing Cip7-GFP or Cip7-RT. TrueCut Cas9 was used as a control. Cas9-Doc1 or TrueCut Cas9 associated with target DNA is indicated by a downward arrow in the corresponding figure, and complexes with Cip7-RT or Cip7-GFP are indicated by an upward arrow in the corresponding figure.
[0124] Fig. 7A RNP-transfected potato protoplasts in different conditions in bright field (left) and UV light (right) are shown. a, Negative control (NC) shows no GFP signal. b, In Cip7-GFP-transfected protoplasts, GFP signal is clearly visible. c, Protoplasts transfected with Cip7-GFP and Cas9-Doc1 show more frequent green fluorescence compared to Cip7-GFP alone. Scale bar 150 μm.
[0125] Figure 7B Potato protoplasts transfected with both Cip7-GFP and Cas9-Doc1 are shown in bright field (left) and under UV light (right). a, Intact protoplasts with strong autofluorescence do not give any obvious signs of GFP signal. b, Protoplasts with less autofluorescence appear more yellow to green in color, indicating the presence of GFP. c, Broken protoplasts and cell debris show increased green fluorescence. Scale bar 10 μm.
[0126] Example - Creating a modular CRISPR system
[0127] 1. Materials and Methods
[0128] 1.1 Annealing of oligonucleotides for cloning
[0129] Oligonucleotides were diluted to 100 μM and 20 μL of both strands were mixed with 20 μL of 5M NaCl solution and 20 μL of water (sequences are listed in Table 1 below). The mixture was heated to 95°C and cooled to room temperature. Annealed DNA fragments were diluted to appropriate concentrations and used for cloning.
[0130] 1.2 Molecular cloning
[0131] Table 1: Fragments and plasmids used for cloning
[0132]
[0133] The T7 expression vector pMJ806 (Addgene #39312) carrying the SpCas9 gene was digested with ThermoFisher FastDigest restriction enzymes (RE) XhoI and SpeI. The fragments were separated by 1.2% agarose gel electrophoresis and purified using the ThermoFisher GeneJET gel extraction kit according to the manufacturer's instructions. The DNA concentration was determined spectrophotometrically using a DeNovix DS-11 device.
[0134] The 83bp DNA fragment RBS-NLS (Table 1) generated by oligonucleotide annealing was digested with XhoI and SpeI and purified with the ThermoFisher GeneJet PCR purification kit. ThermoFisher T4 DNA ligase was used to connect in a 20 μL reaction at a plasmid: insert ratio of 1:50. The ligation reaction was diluted 5 times and 2 μL was used to transform ThermoFisher OneShot Top10 chemically competent E. coli cells by 42°C heat shock according to the manufacturer's instructions. 75 μL of transformed cells were plated on LB agar plates supplemented with 50 μg / mL kanamycin and incubated at 37°C overnight. Pick colonies to inoculate 5 mL LB overnight culture, purify plasmids using the ThermoFisher GeneJET plasmid miniprep kit, and verify correct connection by restriction analysis.
[0135] The IDT gBlock Doc1-NLS DNA fragment (Table 1) was inserted by digestion and ligation using SacI and XhoI as described previously. For ligation, a plasmid:insert ratio of 1:3 was used, generating the pMC:RBS-NLS-Cas9-Doc1 construct. As previously described, pMC:Cip7-GFP was generated by removing the unwanted tags in pET30-R5-GFP (Addgene #17838) and replacing them with the 46 bp DNA fragment RBS (oligonucleotide annealing) using XbaI and BglII at a plasmid:insert ratio of 1:50. In a second step, Cip7 from a synthetic DNA fragment (IDT gBlock) was introduced using BglII and KpnI at a plasmid:insert ratio of 1:3 as described previously. MMLV-RT from pET-19b_MMLV-RT (Addgene #153312) was cut with NdeI and XhoI and ligated into pMC:Cip7-GFP at a plasmid:insert ratio of 1:3, replacing the GFP gene and generating pMC:Cip7-RT. Plasmid sequences were confirmed by Sanger sequencing using the primers listed in Table 2.
[0136] Table 2. Primers used for sequencing
[0137] name sequence SEQ ID NO: RBS-NLS-Cas9-Doc1#1 GGCGTAGAGGATCGAGAT SEQ ID NO:5 RBS-NLS-Cas9-Doc1#2 CAAGTGGAGTAGATGCTA SEQ ID NO:6 RBS-NLS-Cas9-Doc1#3 TGCATGGATGACTCGGAA SEQ ID NO:7 RBS-NLS-Cas9-Doc1#4 GACAAGGCGATAGTTTACA SEQ ID NO:8 RBS-NLS-Cas9-Doc1#5 AAACTCGCCAAATCACTAAG SEQ ID NO:9 RBS-NLS-Cas9-Doc1#6 CGTTAAAGAGTTACTAGGGA SEQ ID NO:10 RBS-Cip7-GFP#1=RBS-Cip7-RT#1 GGCGTAGAGGATCGAGAT SEQ ID NO:11 RBS-Cip7-GFP#2 CACTTGTCACTACTTTCTCT SEQ ID NO:12 RBS-Cip7-RT#2 ACGAAACCAGCAAAGAACC SEQ ID NO:13 RBS-Cip7-RT#3 TTTCAAAAACTCACCTACCC SEQ ID NO:14 RBS-Cip7-RT#4 GGTAGAAGCCCTGGTGAAA SEQ ID NO:15
[0138] 1.3 Preparation and transformation of MilliporeSigma Novagen Rosetta (DE3) competent cells
[0139] A frozen stock of MilliporeSigma Novagen Rosetta (DE3) E. coli cells was streaked on LB agar plates and incubated overnight at 37°C. A colony was used to inoculate 5 mL of LB culture, which was incubated overnight at 37°C and 225 rpm. The next day, 50 mL of LB medium was inoculated with 0.5 mL of overnight culture and incubated at 37°C and 225 rpm for 2 h.
[0140] The following steps were performed at 4°C. The culture was cooled on ice for 10 min, centrifuged at 4000×g for 10 min, and the supernatant was decanted. The pellet was resuspended in 10 ml of ice-cold TFB1 buffer (30 nM KOAc, 100 mM RbCl, 10 mM CaCl 2 ·2H 2 O, 50 mM MnCl 2 ·4H 2O, 15% glycerol) and incubated on ice for 5 min. The cells were centrifuged at 4000×g for 10 min, the supernatant was decanted and the pellet was resuspended in 2 ml TFB2 (10 mM MOPS, 75 mM CaCl 2 ·2H 2 O, 10mM RbCl, 15% glycerol), then incubate on ice for 15min. The cells are divided into equal parts, quickly frozen in liquid nitrogen and stored at -80°C. 10ng of the purified plasmid is added to 50μL competent cells and cooled on ice for 30min, then incubated at 42°C for 30s and quickly put back on ice. 100μL ThermoFisher SOC culture medium is added and the cells are grown at 37°C and 225rpm for 1h. 75μL of cells are spread on LB agar plates supplemented with 50μg / mL kanamycin and incubated overnight at 37°C.
[0141] 1.4 Protein expression and purification
[0142] Colonies from LB agar plates were picked and used to inoculate 5 ml of TB medium (Terrific Broth: 1.2% tryptone, 2.4% yeast extract, 0.5% glycerol, 89 mM phosphate) supplemented with 50 μg / mL kanamycin and incubated overnight at 37°C and 225 rpm. 50 ml of TB medium supplemented with 50 μg / mL kanamycin was inoculated with 0.5 mL of overnight culture and grown at 37°C until OD600 = 0.6 was reached. Protein expression was induced with 0.1 mM IPTG, the temperature was reduced to 18°C, and the culture was grown at 225 rpm for 20 h. Cells were harvested by centrifugation at 4000 × g for 20 min, the supernatant was decanted and the pellet was quickly frozen in liquid nitrogen. The pellet was resuspended in 5 mL of binding buffer (Cytiva His phosphate buffer, pH 7.4, 80 mM imidazole, 1 × Thermo Scientific TM Halt TM Protease inhibitor cocktail). Resuspended cells were lysed by ultrasound at 400 Ws / mL using a Hielscher UP400St sonicator. Lysate was clarified by centrifugation at 11,000 × g for 15 min. The clarified lysate was applied to a Cytiva His Spintrap column and purified according to the manufacturer's instructions. In brief, the storage solution was removed and the column was balanced with binding buffer. The clarified lysate was applied and the column was washed once with binding buffer. The bound protein was eluted in two fractions using elution buffer (Cytiva His phosphate buffer, pH 7.4, 500 mM imidazole).
[0143] Protein concentration was determined using the Thermo Scientific Coomassie (Bradford) protein assay kit according to the manufacturer's instructions. A standard microplate protocol with a working range of 100-1500 μg / mL was used and absorbance was measured at 595 nm in a ThermoScientific Multiskan GO microplate spectrophotometer. Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was used to evaluate the purification process.
[0144] 1.5 SDS-PAGE
[0145] Protein samples were mixed with Novex TM Tris-glycine SDS sample buffer (2×) was mixed, incubated at 85°C for 5 min, and loaded onto 10% Novex TM Tris-glycine gel. Load unstained Thermo Scientific PageRuler to determine molecular weight. TM Run at 120 V in Tris-Glycine SDS running buffer until the dye front reaches the bottom of the gel. Carefully remove the gel from the plastic box, wash three times in MilliQ water for 5 min each, and re-cleave on the GelCode TM Stain in blue staining reagent for 1 h. Imaged using the Bio-Rad ChemiDoc Touch imaging system. Run distances were measured in Fiji ImageJ, and standard curves were created by linear regression in Microsoft Excel and the molecular weight of the purified protein was estimated:
[0146] MW=10 (mx+n) (1)
[0147] Where m is the slope, x is the run distance of the band of interest, and n is the intercept of the standard curve. The standard errors of the slope and intercept are propagated according to the rules of Gaussian error propagation to calculate the error in the estimated molecular weight:
[0148]
[0149] 1.6 Cas9 in vitro cleavage assay
[0150] This protocol was adapted from New England Biolabs, 2014. As DNA substrates, the patatin-1 gene was amplified from an internal unpublished plasmid using PatF: ATGGCAACTACTAAATCTTTTTTAAT (SEQ ID NO: 16) and PatR: TTAATAAGAAGCTTTGTTTGCTCGG (SEQ ID NO: 17) by PCR (7s 98°C, 20s 60°C, 25s 72°C, 30 cycles) and purified using the ThermoFisher GeneJET PCR cleanup kit. The activity of the Cas9 nuclease was confirmed using a previously validated gRNA (PatActT1: GTAATTGGAGGAACAAGTAC (SEQ ID NO: 18)).
[0151] To assemble RNPs, 30 nM Cas9 (ThermoFisher TrueCut Cas9v2 as a control or purified Cas9-Doc1) and 30 nM gRNA were mixed and incubated in Cas9 nuclease reaction buffer (20 mM HEPES, 100 mM NaCl, 5 mM MgCl). 2 , 100 nM EDTA) at 25 ° C for 10 min. Subsequently, the substrate DNA was added at a final concentration of 3 nM to obtain a ratio of 10:10:1 (Cas9: gRNA: substrate DNA), and the reaction was incubated at 37 ° C for 1 h. Then 1 μL of proteinase K was added and incubated at 65 ° C for 10 min, and finally the reaction was analyzed on a 2% agarose gel.
[0152] 1.7 Native PAGE
[0153] Protein samples were diluted to 0.5-2pmol / μL concentration, mixed with sample buffer (final concentration: 100mM TrisHCl, 10% glycerol, 0.00025% bromophenol blue, pH 8.6) and incubated at room temperature for 5min. Samples were loaded onto 10% Invitrogen Novex Tris-glycine gels and run on ice at 200V in non-denaturing running buffer (25mM Tris alkali, 192mM glycine, pH 8.3) until the dye front reaches the bottom of the gel. GFP imaging was performed in the Pro-Q Emerald 488 setting of the device using the Bio-Rad ChemiDocTouch imaging system.
[0154] 1.8 Cas9-electrophoretic mobility shift assay (EMSA)
[0155] The Cas9 in vitro cleavage assay is suitable for studying the interaction of Cas9-Doc1 with Cip7-GFP and Cip7-RT. To visualize GFP, 2 pmol of both Cas9-DOC1 and Cip7-GFP were used per 20 μL reaction to obtain significant GFP signals. For more obvious bands in Biotium GelRed imaging, 1 pmol of Cas9-DOC1 and increasing concentrations of Cip7-GFP or Cip7-RT (1, 2, 4, 6, 8 pmol) were used. ThermoFisher TrueCut v2Cas9 was used as a control. Cas9-Doc1, Cip7-GFP or Cip7-RT and gRNA were mixed and pre-incubated in Cas9 reaction buffer at 25°C for 10 min. Target DNA was added after pre-incubation at a molar ratio of 10:10:1 (Cas9:gRNA:DNA), and the reaction was incubated at 37°C for exactly 30 min. The test tubes were immediately cooled on ice and then loaded onto a 1% agarose gel and run at 4V / cm. GFP signal was imaged using the Bio-Rad ChemiDoc Touch imaging system in the instrument's Pro-Q Emerald 488 setting. Post-staining was performed in 3× Biotium GelRed solution for 20 min before imaging the gel using the instrument's Biotium GelRed setting.
[0156] 1.9 Protoplast isolation, transfection and regeneration
[0157] Protoplasts were isolated, transfected, and regenerated according to the protocol of Andersson et al. 2018. Briefly, leaves from 4 to 6-week-old in vitro potato (S. tuberosum) variety Desiree plants were used for protoplast isolation. 1-2 g of leaves were incubated at 4 ° C for 24 h in a petri dish with 20 mL of conditioned medium (2.7 g / L MS salts, 0.001% Nitsch & Nitsch vits, 100 mg / L casein hydrolysate, 2 mg / L NAA, 0.5 mg / L BAP, pH 5.8). The leaves were cut into 1 mm wide slices and incubated in 20 ml of plasmolysis solution (0.5 M D-sorbitol) for 30 min. The cells were stirred for 2 h with 25 mL of enzyme solution (1×Macro, 1×Fe / EDTA, 1×Micro, 0.5×Vits 1, 0.5×Vits 2, 0.5×Vits 3, 5×Nitsch&Nitsch vits, 1×Organic, 500 mg / L casein hydrolysate, 0.205 M D-glucose-monohydrate, 0.205 M mannitol, 20 g / L PVP-10, 5.37 μM 1-naphthaleneacetic acid, 1.78 μM 6-benzylaminopurine, 10 g / L Cellulase R10, 2 g / L Maceroen-zyme R10, 6 mM CaCl 2 ·2H 2 O, pH 5.6) and incubated at 25°C for 14 h. The protoplast solution was filtered through 100 μM and 70 μM filters and then centrifuged at 50×g for 5 min. The protoplast pellet was resuspended in 2 mL of washing solution (1×Macro, 6 mM CaCl 2 ·2H 2 O, 1×Micro, 240mM NaCl, 10.74μM 1-naphthaleneacetic acid, 2.22μM 6-benzylaminopurine, 1×Fe / EDTA, pH 5.6) and carefully applied to a test tube containing 6mL sucrose solution (0.43M sucrose). Centrifuge at 50×g for 15min. Carefully transfer the protoplasts to transformation buffer 1 (190mM mannitol, 100mM CaCl 2 ·2H 2 O, 0.5% MES, pH 5.6) and counted in a Fuchs-Rosenthal counting chamber, centrifuged at 50×g for 10 min, and resuspended in transformation buffer 2 (0.5 M mannitol, 15 mM MgCl 2 6H 2 O, 0.1% MES, pH 5.6) to 1.6 × 10 6pps / mL. 1.5 nmol gRNA (PatActT1: GTAATTGGAGGAACAAGTAC (SEQ ID NO: 18)) and 10 μg CIP7-GFP or reaction buffer (20 mM HEPES, 100 mM NaCl, 5 mM MgCl 2 , 100nM EDTA) was pre-incubated with 5μg of Cas9 at room temperature (RT) for 15min. 100000pps was added to each reaction together with 120μL 40% polyethylene glycol (PEG) and incubated at room temperature for 30min. 5mL of washing solution was added and the protoplasts were centrifuged at 50×g for 5min. For microscopy, the protoplasts were resuspended in 50μL of washing solution and imaged using a Leica DMLB fluorescence microscope. For cell division, the protoplasts were resuspended in 1ml of medium E (1×Macro, 1×Fe / EDTA, 2.5mM CaCl 2 ·H 2 O, 1×Micro, 0.5×Vits 1, 0.5×Vits 2, 0.5×Vits 3, 1×sugar, 1×organic matter, 500 mg / L casein hydrolysate, 0.17 M D-glucose monohydrate, 0.17 M mannitol, 2 g / L bovine serum albumin, 5.37 μM 1-naphthaleneacetic acid, 1.78 μM 6-benzylaminopurine, pH 5.6), and 1 ml of alginate solution (2.8% alginate sodium salt, 0.4 M sorbitol) was added for embedding. The protoplasts were incubated at 25° C. in the dark for 5 days. In the following 14 days, the light was gradually increased to 10 μmol / m 2 Emerging calli were imaged and counted using the Analyze Particles tool in Fiji ImageJ.
[0158] 1.10 Statistical analysis
[0159] One-way ANOVA was performed in RStudio (R Core Team, 2022), followed by paired T-test comparisons using the Bonferroni correction method.
[0160] 1.11 Solutions used
[0161] The solutions used and mentioned above are defined in Table 3 below:
[0162] Table 3. Solutions used
[0163]
[0164] 2. Results
[0165] 2.1 Expression constructs
[0166] Three expression constructs were generated using molecular cloning as a first step toward a modular interacting CRISPR system for RNP delivery ( Figure 2A In the T7 expression vector carrying the SpCas9 gene, the undesired tag at the N-terminus was replaced with a short sequence containing the ribosome binding site (RBS) and the nuclear localization sequence (NLS). The Dockerin domain Doc1 was added to the C-terminus to generate the first construct Cas9-Doc1 ( Figure 2A , upper figure). For the second T7 expression vector carrying the GFPuv gene, the RBS was again added to the N-terminus together with the cohesin domain Cip7, which resulted in the second construct Cip7-GFP ( Figure 2A , middle). In the final step, GFPuv was replaced by Moloney murine leukemia virus reverse transcriptase (MMLV-RT) to generate Cip7-RT ( Figure 2A ,bottom).
[0167] Using the T7 expression system, these constructs are used to produce recombinant proteins in Escherichia coli and subsequently deliver RNPs in potato protoplasts. All three constructs are under the control of the T7 promoter, which is recognized by the T7 RNA polymerase and allows strict control of gene expression in E. coli strains carrying the gene for the T7 RNA polymerase. In addition, all three constructs have kanamycin resistance (KanR) for selecting successfully transformed colonies. The first construct starts with an NLS to signal the import of the recombinant protein into the nucleus. The SpCas9 gene is adjacent to the NLS and encodes the SpCas9 protein, which is the core of the CRISPR system. The Dockerin domain Doc1 represents the first binding peptide, also referred to herein as an adapter, and will be able to couple other functional proteins to Cas9. Finally, the 6×His tag allows protein purification. The recombinant protein produced by this construct will be referred to as Cas9-Doc1 hereinafter. The second construct starts with a 6×His-tag for purification, followed by a second binding peptide or a second adapter component, i.e., the cohesin domain Cip7 that can bind to the Doc1 domain. GFPuv is a variant of the wild-type green fluorescent protein (GFP) and is optimized for excitation by UV light. Here, GFPuv serves as a reporter for the proof-of-principle phase. The corresponding recombinant protein will be named Cip7-GFP. The last construct is similar to the second one, but GFP is replaced by MMLV-reverse transcriptase, which is used in the primed editing system. Hereinafter, this construct will be referred to as Cip7-RT.
[0168] The constructed expression vector was used to transform Rosetta (DE3) E. coli cells, and successful transformation was verified by restriction analysis ( Figure 2B ). Plasmid DNA was isolated from transformed and untransformed Rosetta (DE3) cells. Isolated plasmid DNA was digested with HindIII and BglII together with the corresponding plasmid used for transformation as a positive control. For all three constructs, the restriction patterns of DNA isolated from Rosetta (DE3) cells were almost identical to those of the control. However, in all samples isolated from Rosetta (DE3) cells, including the untransformed control ( Figure 2B , indicated by arrows), an additional band of about 10000 bp can be observed. This band is most likely attributed to the pRARE plasmid carried by the Rosetta (DE3) strain for expressing rare tRNA. The results of restriction analysis indicate successful transformation and allow protein expression to begin.
[0169] 2.2 Protein expression and purification
[0170] Overnight cultures of transformed bacteria were used to inoculate bacterial culture media. The cultures were grown until OD600 = 0.6 was reached, protein expression was induced using 0.1 mM isopropyl-β-D-thiogalactopyranoside (IPTG), and then grown for 20 h at 18 ° C. Bacteria were harvested by centrifugation and lysed by ultrasound. The recombinant protein was purified using immobilized metal affinity chromatography (IMAC) and the process was monitored by SDS-PAGE. The size of the purified protein was predicted using the online tool ExPASy (Gasteiger, 2003, Table 4). The molecular weight of the bands observed in SDS-PAGE was estimated using ThermoScientific PageRuler and the standard curve method. For Cas9-Doc1, the estimate by the standard curve was slightly lower than the ExPASy prediction, while for Cip7-GFP and Cip7-RT it was the opposite (Table 4). The protein concentration in the eluted fraction was determined by the Bradford assay.
[0171] Table 4. Molecular weight and isoelectric point of recombinant proteins.
[0172] protein pI* MW*[kDA] MW**[KDa] Cas9-Doc1 9.13 170 149±20 Cip7-GFP 5.86 47 57±9 Cip7-RT 7.95 94 109±15
[0173] *Estimated by the online tool ExPASy (Gasteiger, 2003), **determined by SDS-PAGE standard curve method. Uncertainties were obtained by error propagation of the standard deviation of the linear regression.
[0174] The protein bands of Cas9-Doc1 and Cip7-GFP appear very prominent in the elution fractions with high contrast to the background, indicating high purity. On the other hand, the Cip7-RT band is darker, which reduces the contrast to the background. Note that for SDS-PAGE, the loading amount was not normalized to the culture volume. The average protein yield was (22±11) mg / L for Cas9-Doc1, (94±31) mg / L for Cip7-GFP and (15±10) mg / L for Cip7-RT. Therefore, Cip7-GFP had the highest yield. Cas9-Doc1 and Cip7-RT are larger in size (Table 4), which is why lower protein yields can be expected.
[0175] When Cip7-RT was grown without IPTG induction, the cultures reached higher OD600 values and higher band intensities compared to the induced samples (data not shown). It was expected that cell growth would be impaired after induction with IPTG, and impairment was also observed for Cas9-Doc1 and Cip7-GFP, although not as severe. In the absence of IPTG, basal expression of protein was seen for all three constructs (data not shown). However, for Cas9-Doc1 and Cip7-GFP, the recombinant protein yields of the IPTG-induced samples were much higher than those of the uninduced controls, while Cip7-RT showed comparable and possibly even higher yields in the uninduced samples. The yield of the uninduced Cip7-RT was almost as high as that induced by Cas9-Doc1, but the induced cultures produced only about half the amount of protein.
[0176] To investigate whether purified Cas9-Doc1 exhibits nuclease activity, an in vitro cleavage assay was performed ( Figure 3 A). The Patatin 1 PCR fragment was incubated with commercial TrueCut Cas9 or purified Cas9-Doc1 and gRNA. The reaction was run on an agarose gel. As target DNA, the Patatin 1 gene was amplified using PCR. A previously validated gRNA was used to cleave the PCR fragment ( Figure 3 B). Commercial Cas9 protein was used as a control. As observed, correct cleavage of the target DNA will produce two cleavage fragments of size 948 bp and 213 bp. The assay clearly shows that the purified Cas9-Doc1 is active and effectively cleaves the target DNA. There is no visible difference in the amount of cleaved DNA compared to commercial Cas9. The assay was repeated after the purified Cas9-Doc1 was stored at -20°C in reaction buffer containing 50% glycerol for 14 days, and no decrease in activity was observed.
[0177] 2.3 Protein-protein interactions
[0178] The interaction of Cas9-Doc1 and Cip7-GFP was examined using native PAGE and in-gel GFP imaging ( Figure 4 ). Cip7-GFP and Cas9-Doc1 were loaded onto a non-denaturing gel with increasing amounts of the latter. TrueCut Cas9 was used as a negative control. The values depicted are in pmol. After electrophoresis, the gel was imaged for GFP signal.
[0179] Specifically, Cas9-Doc1 was mixed with increasing concentrations of Cip7-GFP and incubated at room temperature for 5 min. A commercial Cas9 protein without Doc1 was used as a negative control. When only Cip7-GFP was loaded, a single distinct band was observed ( Figure 4 , Lane 5). When Cas9-Doc1 was added, a second band appeared above the first band, which became stronger as the amount of Cas9-Doc1 increased, while the lower band began to fade ( Figure 4 , lanes 1 to 3). When Cip7-GFP was mixed with commercial Cas9 lacking the Doc1 domain, the upper band could not be observed ( Figure 4 , Lane 6). No band was observed in the lane with only Cas9-Doc1 ( Figure 4 , lane 4). Note that the upper band is located directly below the gel well, and even if the run time is extended, the upper band will not migrate further into the gel. Coomassie staining shows that there is a large amount of protein just below the well, approximately where the upper fluorescent band is observed (data not shown). The intensity gradient of the upper band, which is proportional to the amount of Cas9-Doc1 added, shows the interaction between Cas9-Doc1 and Cip7-GFP. Almost all Cip7-GFP is retained at a ratio of 2:1 (Cas9-Doc1:Cip7-GFP). These results show that the recombinant proteins Cas9-Doc1 and Cip7-GFP bind to each other in an effective and specific manner.
[0180] Previous studies on the expression and purification of cohesin and Dockerin domains reported that due to Ca 2+ Dockerin-dependent binding requires the addition of CaCl to the medium 2 However, under the conditions presented here, when the Cas9-Doc1 growth medium was supplemented with CaCl 2 When compared with no CaCl supplementation 2 In contrast, no differences were found in the interactions (data not shown).
[0181] To further validate the interaction between Cip7-GFP and Cas9-Doc1, especially when noting that the lack of Cas9 entering the gel could pose a problem for the clear evidence of the interaction between Cip7-GFP and Cas9-Doc1, the previously described Cas9 in vitro cleavage assay was adapted into an electrophoretic mobility shift assay (EMSA) as inspired by Künne et al. 2015. Briefly, Cas9 is guided by a gRNA and binds to the target DNA. We attempted to keep Cas9 associated with the target DNA by removing the final heating and protein degradation steps in the cleavage assay and immediately cooling on ice. The main idea is that the negative charge of the target DNA is sufficient to allow the DNA and the associated Cas9 protein to migrate into the gel. The additional mass of Cas9 should cause a mobility shift that can be distinguished from unbound DNA. When Cip7-GFP is added, a fluorescent band can be observed at the position of the mobility shift. Moreover, the additional mass of Cip7-GFP or Cip7-RT coupled to Cas9-Doc1 can lead to an additional mobility shift, which would further confirm the interaction.
[0182] After several rounds of optimization, this idea was transformed into a comprehensive protocol. After preincubation with the recombinant protein, the target DNA was added and the reaction was incubated at 37°C for 30 min. This incubation time was reduced compared to the original cleavage assay to allow time for binding but not complete cleavage.
[0183] After incubation, the reactions were cooled on ice and run at low voltage on an agarose gel without any DNA dye. The gel was imaged for GFP and then post-stained with GelRed to visualize the DNA.
[0184] In samples with Cas9 and gRNA, a DNA band that appears higher than the band corresponding to the uncleaved PCR fragment can be observed ( Figure 5 , GelRed image). No bands were observed when only DNA was loaded (lane 1) or when gRNA was omitted (lane 6). This suggests that the binding of Cas9 to DNA causes a mobility shift as expected. When all three, DNA, Cas9, and gRNA, were present, a lower DNA band was observed that most likely corresponds to the cleaved DNA fragment. Note that the second cleaved DNA fragment is Figure 3, which is shown in the figure, is located at a substantially lower position, but is not shown in the image. When gRNA was omitted (lane 6), no obvious mobility shift band was observed. In all samples to which Cip7-GFP was added, a very significant fluorescent band was shown in the upper part of the gel. Cip7-GFP alone (lane 5) gave a fluorescent band at the same position as other samples, which is why the band can be attributed to free Cip7-GFP. The second different GFP band can only be observed when Cas9-Doc1+Cip7-GFP and gRNA are added to DNA (lane 3, GFP image, white arrow). This band appears to be in the same position as the DNA mobility shift band, indicating the interaction of Cip7-GFP with Cas9-Doc1 (lane 3, merge). When Cas9-Doc1 is replaced by commercial Cas9 lacking the Doc1 domain, no such GFP band can be observed.
[0185] To investigate the interaction of Cip7-RT and Cas9-Doc1, the experiments were repeated with longer run times and overall reduced amounts of DNA and protein to achieve higher band resolution ( Figure 6 ). For comparison, Cip7-GFP and Cas9-Doc1 were included. The GFP imaging step was omitted because the lower amount of Cip7-GFP did not allow for observation of Figure 5 Cas9-Doc1+Cip7-GFP bands are shown, and for Cip7-RT and Cas9-Doc1, the absence of GFP signal is expected. The experimental procedure remained the same, but this time Cip7-RT or Cip7-GFP was added stepwise, respectively.
[0186] For commercial Cas9, the mobility shift band (indicated by arrows) is more prominent and the uncleaved DNA band has disappeared, while for all Cas9-Doc1 samples, the uncleaved DNA band is more prominent than the mobility shift band ( Figure 6 As the amount of Cip7-RT increases, the mobility shift band appears more diffuse and broader until it has approximately twice the width of the initial band ( Figure 6 , upper figure). This could not be observed for the control using commercial Cas9. The wider band is probably due to the predicted additional mobility shift caused by the additional mass of Cip7-RT when coupled to Cas9-Doc1. The lower part of the mobility shift band does not fade with increasing amounts of Cip7-R. A similar situation occurs with Cip7-GFP. The mobility shift band appears to widen with increasing amounts of Cip7-GFP, although not as wide as Cip7-RT. These results show the specific interaction of Cas9 and functional proteins through the adaptor domains Doc1 and Cip7.
[0187] 2.4 RNP transfection
[0188] Potato (Solanum tuberosum) protoplasts were transfected with the purified fusion protein to investigate whether the interaction of Cas9-Doc1 and Cip7-GFP that had been observed in vitro could also be observed in vivo. In addition, it was necessary to assess whether the transfected protoplasts retained the ability to divide cells and therefore whether the purity grade of the fusion protein was sufficient. To this end, protoplasts were isolated from potato leaves and transfected with 40% PEG. Protoplasts transfected with Cip7-GFP, Cip7-GFP+Cas9-Doc1 and negative controls without transfected protein were imaged using fluorescence microscopy with UV as the light source ( Fig. 7A and Figure 7B ). Cas9-Doc1 has an NLS upstream of the SpCas9 gene, which signals its import into the cell nucleus. If Cip7-GFP is coupled to Cas9-Doc1, the complex is likely to be imported and a fluorescent signal is observed in the cell nucleus. Chloroplasts are light-utilizing organelles of plant cells and carry a pigment called chlorophyll, which has an emission maximum at about 730 nm when excited with UV light. Light emitted at this wavelength is perceived by the human eye as red light. The GFP variant GFPuv has an emission maximum at about 506 nm, which is perceived as green light. Note that during the experiments, bandpass filters for autofluorescence and GFP signals were not available, which is why the two can only be distinguished by the colors recorded in the UV images. Typically, the negative control appears as slightly more intact protoplasts than the samples transfected with the recombinant protein ( Fig. 7A , left, images representing multiple observations). In the negative control, a strong autofluorescence signal from chloroplasts was seen in the red light spectrum, and as expected, no green light indicating a GFP signal could be observed ( Fig. 7A , a). Cip7-GFP showed several green spots indicating GFP signals together with autofluorescence ( Fig. 7A , b). Compared with Cip7-GFP alone, Cip7-GFP+Cas9-Doc1 showed a larger amount of GFP signal ( Fig. 7A , c).
[0189] The protoplasts transfected with RNP and functional proteins were embedded in alginate and allowed to divide for more than two weeks. The number of calli was counted as a measure of cell division ability to assess whether the purity of the purified recombinant protein was sufficient for protoplast transfection and regeneration. Compared with other samples with transfected proteins, the number of calli appearing in NC showed a high statistically significant difference. No statistical significance was observed between the samples transfected with recombinant proteins. Interestingly, compared with samples with Cas9-Doc1 and gRNA (about 2 calli per 50000pps), protoplasts transfected only with Cas9-Doc1 showed a slightly higher cell division ability, with 4 calli per 50000pps. In addition to Cas9-Doc1 and gRNA, protoplasts transfected with Cip7-GFP did not show further damage to regeneration (about 2 calli per 50000pps).
[0190] 3. Discussion
[0191] Here, we present the basis of a modular interacting CRISPR system that separates fusion proteins into plug-and-play components, enabling greater flexibility and efficient protein production in bacterial expression systems.
[0192] 3.1 Protein expression
[0193] Even though the molecular weight predicted by ExPASy does not strictly match the molecular weight determined by SDS-PAGE (Table 4), the closest indication is that the band represents a recombinant protein, as some variation is expected when the SDS-PAGE standard curve method is used (Karpe and Hamsten, 1994). It can be assumed that both Cas9-Doc1 and Cip7-GFP were successfully expressed and purified in Rosetta (DE3) E. coli cells using the T7 expression system. A high degree of purity could be obtained, as assessed by SDS-PAGE. For Cas9-Doc1, the average yield of (22 ± 11) mg / L is consistent with the report on SpCas9 fusion proteins by Fleitas et al., 2022. The Cas9 in vitro cleavage assay showed that the purified Cas9-Doc1 was active, and no activity differences could be observed compared to commercial Cas9. Therefore, the Dockerin domain Doc1 does not impair the nuclease activity of Cas9.
[0194] For Cip7-RT, the uninduced protein yield almost reached the amount of induced Cas9-Doc1, and the induced yield was only half of that. The low yield of the induced Cip7-RT culture may indicate the toxicity of large amounts of protein and mark the need for further optimization of culture conditions. Culture media without expression inducing agents and different temperatures and growth times may provide better yields for Cip7-RT. In addition, co-expression of T7 lysozyme has previously been shown to provide tighter control of protein expression (Spehr et al., 2000). When T7 polymerase is substantially expressed, T7 lysozyme can inhibit T7 polymerase, which allows for tighter control and at the same time allows for easier cell lysis using freeze-thaw cycles (Wanarska et al., 2007).
[0195] In summary, the possibility to easily produce proteins in modular CRISPR-Cas systems is an advantage over current approaches that require extensive optimization procedures or employ much more costly eukaryotic expression systems.
[0196] 3.2 Protein-protein interaction studies
[0197] Native PAGE with in-gel GFP imaging effectively illustrates the interaction between Cas9-Doc1 and Cip7-GFP ( Figure 4 ). EMSA was then used to confirm the interaction between Cas9-Doc1 and Cip7-GFP ( Figure 5 ). Only in the sample with Cas9-Doc1 and Cip7-GFP, GFP signal could be observed at the position of the mobility shift band ( Figure 5 , lane 3). This also shows the interaction between Cas9-Doc1 and Cip7-GFP when they are bound to DNA. In addition, in the absence of gRNA, no mobility shift of the DNA band was observed, demonstrating the specificity of the purified Cas9-Doc1 ( Figure 5 , lane 5). When Cip7-GFP or Cip7-RT was added, the assay was repeated with longer run times to visualize additional band shifts, confirming the interactions already observed for Cas9-Doc1 and Cip7-GFP and for Cas9-Doc1 and Cip7-RT ( Figure 6 ).
[0198] As evidenced by the band width, the addition of Cip7-RT appeared to cause a stronger mobility shift than the addition of Cip7-GFP. This may be due to the smaller size of Cip7-GFP, which is only about half that of Cip7-RT (Table 4).
[0199] 3.3 Protoplast transfection
[0200] Potato protoplasts transfected with Cip7-GFP showed distinct green fluorescent spots, indicating that sufficient amounts of the recombinant protein were used for transfection ( Fig. 7A ).
[0201] Protoplasts transfected with the recombinant protein clearly showed reduced viability compared to protoplasts treated with 40% PEG alone. This may demonstrate the stress caused by the process on the cells. Although not significant, the commercial TrueCut Cas9 showed a trend towards achieving higher cell division capacity than the purified Cas9-Doc1. This may indicate that higher purity of commercial Cas9-Doc1 leads to better cell division capacity, pointing to the advantage of further purification steps. A plausible reason for this observation could be that there are traces of bacterial compounds in the purified protein sample that cause an increased immune response in the protoplasts, where the pathogen triggers the immune response of the protoplasts and induces cell death. Rajagopalan et al. 2018 describe a two-step method for obtaining highly pure Cas9 protein involving a cation exchange chromatography step after IMAC purification. The additional step can achieve higher purity and therefore better protoplast regeneration, and this two-step method can be used when producing CRISPR-Cas proteins.
[0202] Cas9-Doc1 without gRNA appeared to achieve slightly higher cell division capacity than samples with gRNA, which may indicate cell stress caused by nuclease activity. On the other hand, adding Cip7-GFP to Cas9-Doc1 and gRNA did not show any further impairment of cell division.
[0203] 3.4 Conclusion
[0204] This embodiment shows that the modular interaction CRISPR system can expand the molecular toolbox for RNP delivery methods. The expression and purification of the first component, Cas9 protein and its Dockerin binding peptide (Cas9-Doc1) and functional protein (reverse transcriptase and its cohesion binding peptide (Cip7-RT)) are successful and will pave the way for the further development of the system. These components can be mass-produced in bacterial cells, thereby providing better cost efficiency and thus increasing the accessibility of CRISPR-Cas gene editing. The results also show that Cas9-Docl is coupled to Cip7-GFP and Cip7-RT as expected into a complex, whereby Cas9 retains the ability to bind and cleave DNA. Protoplasts can be transfected with recombinant proteins, and the results show that cell division is successful. By freely combining different components, higher flexibility is achieved. This modular system has great prospects, especially in changing the way genome editing shapes sustainable food production.
[0205] References
[0206] Andersson,M.,Turesson,H.,Olsson,N., A.-S.,Ohlsson,P.,Gonzalez,M.N.,Samuelsson,M.,&Hofvander,P.(2018).Genome editing in potato via CRISPR-cas9ribonucleoprotein delivery.Physiologia Plantarum,164(4),378-384.https: / / doi.org / 10.1111 / ppl.12731
[0207] Fleitas,A.L., M.,&Vidal,S.(2022).A robust expression andpurification method for production of SpCas9-GFP-MBP fusion protein forinvitro applications.Methods and Protocols,5(3),44.https: / / doi.org / 10.3390 / mps5030044
[0208] Gasteiger,E.(2003).ExPASy:The proteomics server for in-depth proteinknowledge and analysis.Nucleic Acids Research,31(13),3784-3788.https: / / doi.org / 10.1093 / nar / gkg563
[0209] Karpe,F.,&Hamsten,A.(1994).Determination of apolipoproteins b-48andb-100in triglyceride-rich lipoproteins by analytical SDS-PAGE Journal ofLipid Research,35(7),1311-1317.https: / / doi.org / 10.1016 / s0022-2275(20)39974-0
[0210] Künne,T.,Westra,E.R.,&Brouns,S.J.J.(2015).Electrophoretic mobilityshift assay of DNA and CRISPR-cas ribonucleoprotein complexes.Methods inmolecular biology(pp.171-184).Springer New York.https: / / doi.org / 10.1007 / 978-1-4939-2687-9_11
[0211] New England Biolabs.(2014).In vitro digestion of dna with cas9nuclease,s.pyogenes(m0386).protocols.io.https: / / doi.org / dx.doi.org / 10.17504 / protocols.io.ch2t8d
[0212] R Core Team.(2022).R:A language and environment for statisticalcomputing.R Foundation for Statistical Computing.Vienna,Austria.https: / / www.R-project.org /
[0213] Rajagopalan,N.,Kagale,S.,Bhowmik,P.,&Song,H.(2018).A two-step methodfor obtaining highly pure cas9 nuclease for genome editing,biophysical,andstructural studies.Methods and Protocols,1(2),17.https: / / doi.org / 10.3390 / mps1020017
[0214] Rees,H.A.,Komor,A.C.,Yeh,W.-H.,Caetano-Lopes,J.,Warman,M.,Edge,A.S.B.,&Liu,D.R.(2017).Improving the DNA specificity and applicability ofbase editing through protein engineering and protein delivery.NatureCommunications,8(1).https: / / doi.org / 10.1038 / ncomms15790
[0215] Spehr,V.,Frahm,D.,&Meyer,T.F.(2000).Improvement of the t7 expressionsystem by the use of t7 lysozyme.Gene,257(2),259-267.https: / / doi.org / 10.1016 / s0378-1119(00)00400-5
[0216] Wanarska,M.,Hildebrandt,P.,&Kur,J.(2007).A freeze-thaw method fordisintegration of escherichia coli cells producing t7 lysozyme used in pbadexpression systems.Acta biochimica Polonica,54,671-672.。
Claims
1. A modular CRISPR-Cas system for ribonucleoprotein (RNP) delivery, comprising: - a CRISPR-Cas protein fused to a first binding peptide, - a functional protein fused to a second binding peptide, Wherein the first binding peptide and the second binding peptide are configured to bind to each other and define a binding peptide pair.
2. The modular CRISPR-Cas system of claim 1, wherein the functional protein is configured to alter the outcome of the action of the CRISPR-Cas protein on DNA.
3. A modular CRISPR-Cas system according to any of the preceding claims, wherein the binding peptide pair comprises a cohesin / Dockerin system.
4. The modular CRISPR-Cas system according to any one of the preceding claims, wherein the functional protein is selected from the group consisting of: a) a deaminase, preferably a modified deaminase, b) reverse transcriptase, c) methylase, and d) Homologous recombination and homology-directed repair enhancing proteins.
5. The modular CRISPR-Cas system according to any one of the preceding claims, further comprising: - A guide RNA sequence complex bound to the CRISPR-Cas protein.
6. The modular CRISPR-Cas system according to any one of the preceding claims, comprising: - a first container containing said CRISPR-Cas protein fused to said first binding peptide, and - a second container comprising said functional protein fused to said second binding peptide.
7. The modular CRISPR-Cas system of any one of claims 1-6, wherein the CRISPR-Cas protein fused to the first binding peptide and the functional protein fused to the second binding peptide are provided in separate buffer solutions.
8. The modular CRISPR-Cas system of any one of claims 1-6, wherein the CRISPR-Cas protein fused to the first binding peptide and the functional protein fused to the second binding peptide are provided in a solid form, such as a dried form or a crystalline form.
9. The modular CRISPR-Cas system according to any one of the preceding claims, further comprising: - an additional functional protein fused to a third binding peptide, wherein the additional functional protein is different from the functional protein, and wherein the third binding peptide is configured to bind to the first binding peptide, and wherein the third binding peptide preferably has the same amino acid sequence as the second binding peptide, and wherein the modular CRISPR-Cas system preferably further comprises: - a third container comprising said additional functional protein fused to said third binding peptide.
10. A modular CRISPR-Cas system according to claim 9, wherein the additional functional protein fused to the third binding peptide is provided in a separate buffer solution or in a solid form, such as a dried form or a crystalline form.
11. A method for assembling a CRISPR-Cas complex for ribonucleoprotein (RNP) delivery , The following steps are involved: i. Providing a system according to any one of the preceding claims, and ii. bringing the CRISPR Cas protein fused to the first binding peptide and the functional protein fused to the second binding peptide into contact with each other, The method preferably further comprises the following steps: iii. contacting the CRISPR Cas protein with a guide RNA sequence.
12. The method of claim 11, wherein step ii comprises mixing the CRISPR Cas protein fused to the first binding peptide with the functional protein fused to the second binding peptide.
13. The method according to any one of claims 11-12, wherein the CRISPR-Cas protein and its first binding peptide and the functional protein and its second binding peptide are provided in separate buffer solutions such that the buffer solutions can be mixed to assemble the CRISPR-Cas complex.
14. A CRISPR-Cas complex for ribonucleoprotein (RNP) delivery, comprising: - a CRISPR-Cas protein fused to a first binding peptide, - a functional protein fused to a second binding peptide, wherein the first binding peptide and the second binding peptide bind to each other, And wherein the CRISPR-Cas complex preferably further comprises: - A guide RNA sequence complex bound to the CRISPR-Cas protein.
15. Use of the modular CRISPR-Cas system for ribonucleoprotein (RNP) delivery according to any one of claims 1 to 10 or the CRISPR-Cas complex for ribonucleoprotein (RNP) delivery according to claim 14 for modifying the genome of an organism, wherein the organism is preferably a plant selected from the group consisting of monocotyledons and dicotyledons, or the organism is a plant selected from the group consisting of: corn, rice, sorghum, rye, barley, wheat, millet, oats, sugarcane, lawn grass or switchgrass, soybean, rapeseed, alfalfa, sunflower, cotton, tobacco, peanut, potato, sugar beet, grape, Arabidopsis and safflower, and wherein preferably the organism is a plant from the Solanaceae family, preferably from the genus Solanum, more preferably from the species Solanum tuberosum.
Citation Information
Patent Citations
Targeted gene activation in plants
US20200017869A1
Prime editing technology for plant genome engineering
WO2021165508A1
Cited By
DCAPS molecular marker for identifying character of grain number per ear of wheat and application of dCAPS molecular marker
CN121852588A
